Cargando…
In a Subgroup of High-Risk Asians, Telmisartan Was Non-Inferior to Ramipril and Better Tolerated in the Prevention of Cardiovascular Events
BACKGROUND AND OBJECTIVES: Results of the recently published ONTARGET study (The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) showed that telmisartan (80 mg/day) was non-inferior to ramipril (10 mg/day) in reducing cardiovascular events. Clinicians in Asia doubt...
Autores principales: | Dans, Antonio L., Teo, Koon, Gao, Peggy, Chen, Jyh-Hong, Jae-Hyung, Kim, Yusoff, Khalid, Chaithiraphan, Suphachai, Zhu, Jun, Lisheng, Liu, Yusuf, Salim |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3006195/ https://www.ncbi.nlm.nih.gov/pubmed/21200437 http://dx.doi.org/10.1371/journal.pone.0013694 |
Ejemplares similares
-
RP-HPLC Estimation of Ramipril and Telmisartan in Tablets
por: Kurade, V. P., et al.
Publicado: (2009) -
Angioedema due to fixed dose combination of telmisartan plus ramipril
por: Tandon, Vishal R., et al.
Publicado: (2014) -
Effects of Telmisartan on Glucose Levels in People at High Risk for Cardiovascular Disease but Free From Diabetes: The TRANSCEND study
por: Barzilay, Joshua I., et al.
Publicado: (2011) -
Prevention and Intervention Studies with Telmisartan, Ramipril and Their Combination in Different Rat Stroke Models
por: Thoene-Reineke, Christa, et al.
Publicado: (2011) -
Comparison of endothelial function improvement estimated with reactive hyperemia index between ramipril and telmisartan in hypertensive patients
por: Ki, You-Jeong, et al.
Publicado: (2017)